Other

Legal payments remaining to be excluded from calculation of consolidated EBITDA

Boston Scientific Legal payments remaining to be excluded from calculation of consolidated EBITDA decreased by 0.6% to $1.41B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 2.5%, from $1.44B to $1.41B.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ1 2019
Last reportedQ3 2025
Metric ID: other_legal_payments_remaining_to_be_excluded_from_calcu_aeabb1

Historical Data

14 periods
 Q2 '21Q3 '21Q1 '22Q2 '22Q3 '22Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25
Value$1.30B$1.24B$1.11B$1.08B$891.00M$1.42B$1.41B$1.49B$1.46B$1.45B$1.44B$1.43B$1.41B$1.41B
QoQ Change—-4.6%-10.9%-2.5%-17.5%+59.8%-0.8%+5.7%-2.5%-0.6%-0.4%-0.9%-1.0%-0.6%
YoY Change———-17.1%-28.3%+28.5%+30.8%+67.7%+2.3%+2.5%-3.5%-1.9%-2.3%-2.5%
Range$891.00M – $1.49B
CAGR+2.4%
Avg YoY Growth+6.9%
Median YoY Growth-1.9%
Current Streak6 quarters decline

Frequently Asked Questions

What is Boston Scientific's legal payments remaining to be excluded from calculation of consolidated ebitda?
Boston Scientific (BSX) reported legal payments remaining to be excluded from calculation of consolidated ebitda of $1.41B in Q3 2025.
How has Boston Scientific's legal payments remaining to be excluded from calculation of consolidated ebitda changed year-over-year?
Boston Scientific's legal payments remaining to be excluded from calculation of consolidated ebitda decreased by 2.5% year-over-year, from $1.44B to $1.41B.